Drug intelligence / Profile preview

AD17002-SC

Development stage: Discontinued
Lead developer: Advagene
Modality: Recombinant Proteins and Enzymes
Administration: Intranasal

Overview

AD17002-SC is Advagene's intranasal COVID-19 immunotherapy based on LTh (αK), a genetically detoxified *Escherichia coli* heat-labile enterotoxin protein. It is designed as a host-directed mucosal innate-immunity activator rather than a SARS-CoV-2 antigen-specific vaccine: intranasal administration is intended to induce epithelial type I and type III interferon responses, reduce viral replication, and support recovery in mild-to-moderate COVID-19. The COVID-19 program generated Phase IIa clinical data, while the subsequent Phase II/III COVID-19 study was terminated. ([advagene.com.tw](https://www.advagene.com.tw/introduction))

Other names: COVID-19 immunotherapyCOVID19 immunotherapyCOVID 19 immunotherapyLTh (αK)新冠肺炎免疫治療

Beyond the preview

Go deeper on AD17002-SC.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AD17002-SC.

Explore the full profile